{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:14:35Z","timestamp":1767928475559,"version":"3.49.0"},"reference-count":10,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Since 2008, the College of American Pathologists has provided the human papillomavirus for cytology laboratories (CHPV) proficiency testing program to help laboratories meet the requirements of the Clinical Laboratory Improvement Amendments of 1988.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives.\u2014<\/jats:title>\n                    <jats:p>To provide an update on trends in proficiency testing performance in the College of American Pathologists CHPV program during the 4-year period from 2011 through 2014 and to compare those trends with the preceding first 3 years of the program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Responses of laboratories participating in the CHPV program from 2011 through 2014 were analyzed using a nonlinear mixed model to compare different combinations of testing medium and platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>In total, 818 laboratories participated in the CHPV program at least once during the 4 years, with participation increasing during the study period. Concordance of participant responses with the target result was more than 98% (38\u2009280 of 38\u2009892). Overall performance with all 3 testing media\u2014ThinPrep (Hologic, Bedford, Massachusetts), SurePath (Becton, Dickinson and Company, Franklin Lakes, New Jersey), or Digene (Qiagen, Valencia, California)\u2014was equivalent (P = .51), and all 4 US Food and Drug Administration (FDA)\u2013approved platforms\u2014Hybrid Capture 2 (Qiagen), Cervista (Hologic), Aptima (Hologic), and cobas (Roche Molecular Systems, Pleasanton, California)\u2014outperformed laboratory-developed tests, unspecified commercial kits, and other (noncommercial) methods in ThinPrep medium (P &amp;lt; .001). However, certain off-label combinations of platform and medium, most notably Cervista with SurePath, demonstrated suboptimal performance (P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Laboratories demonstrated proficiency in using various combinations of testing media and platforms offered in the CHPV program, with statistically significant performance differences in certain combinations. These observations may be relevant in the current discussions about FDA oversight of laboratory-developed tests.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2015-0526-cp","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T09:54:19Z","timestamp":1472032459000},"page":"1371-1374","source":"Crossref","is-referenced-by-count":4,"title":["Update on the College of American Pathologists Experience With High-Risk Human Papillomavirus Proficiency Testing for Cytology"],"prefix":"10.5858","volume":"140","author":[{"given":"Mohiedean","family":"Ghofrani","sequence":"first","affiliation":[{"name":"From the Department of Pathology, PeaceHealth Laboratories, Vancouver, Washington (Dr Ghofrani); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Zhao); University of Central Florida College of Medicine, Orlando (Drs Davey and Husain); the Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Fan); the Department of Patholo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane D.","family":"Davey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujtaba","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Laser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idris T.","family":"Ocal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rulong Z.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhona J.","family":"Souers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Crothers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"issue":"40","key":"2020081222255807400_i1543-2165-140-12-1371-b01","first-page":"7001","article-title":"Clinical laboratory improvement amendments of 1988: final rule\u2014standard; virology","volume":"57","author":"Department of Health and Human Services","year":"1992","journal-title":"Fed Regist"},{"issue":"5","key":"2020081222255807400_i1543-2165-140-12-1371-b02","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5858\/arpa.2012-0149-CP","article-title":"The College of American Pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories","volume":"137","author":"Moriarty","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"2020081222255807400_i1543-2165-140-12-1371-b03","doi-asserted-by":"crossref","first-page":"757","DOI":"10.5858\/arpa.2014-0393-CP","article-title":"Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey","volume":"139","author":"Zhao","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2020081222255807400_i1543-2165-140-12-1371-b04","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/dc.21161","article-title":"Comparison of methods trial for high-risk HPV","volume":"38","author":"Kurtycz","year":"2010","journal-title":"Diagn Cytopathol"},{"issue":"10","key":"2020081222255807400_i1543-2165-140-12-1371-b05","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/JCM.01928-14","article-title":"Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results","volume":"52","author":"Binnicker","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"9","key":"2020081222255807400_i1543-2165-140-12-1371-b06","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfill criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2020081222255807400_i1543-2165-140-12-1371-b07","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cncr.22285","article-title":"Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method","volume":"108","author":"Ko","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"2020081222255807400_i1543-2165-140-12-1371-b08","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/dc.23243","article-title":"Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath\u2122 specimens in the prediction of cervical high-grade squamous lesions","volume":"43","author":"Zhou","year":"2015","journal-title":"Diagn Cytopathol"},{"issue":"2","key":"2020081222255807400_i1543-2165-140-12-1371-b09","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5858\/arpa.2015-0027-OA","article-title":"A comparison of the Roche Cobas HPV Test with the Hybrid Capture 2 Test for the detection of high-risk human papillomavirus genotypes","volume":"140","author":"Levi","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2020081222255807400_i1543-2165-140-12-1371-b10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2014-0012-OA","article-title":"Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population","volume":"139","author":"Alameda","year":"2015","journal-title":"Arch Pathol Lab Med"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/12\/1371\/1615121\/arpa_2015-0526-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/12\/1371\/1615121\/arpa_2015-0526-cp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:09Z","timestamp":1764790509000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/140\/12\/article-p1371.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2015-0526-cp","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}